JP7219213B2 - (r)-2-アミノ-3-フェニルプロピルカルバメートの溶媒和物フォーム - Google Patents
(r)-2-アミノ-3-フェニルプロピルカルバメートの溶媒和物フォーム Download PDFInfo
- Publication number
- JP7219213B2 JP7219213B2 JP2019512895A JP2019512895A JP7219213B2 JP 7219213 B2 JP7219213 B2 JP 7219213B2 JP 2019512895 A JP2019512895 A JP 2019512895A JP 2019512895 A JP2019512895 A JP 2019512895A JP 7219213 B2 JP7219213 B2 JP 7219213B2
- Authority
- JP
- Japan
- Prior art keywords
- apc
- composition
- temperature
- subject
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/08—Separation; Purification; Stabilisation; Use of additives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
本発明は、2016年9月6日付で提出された米国仮出願第62/383,822号に対して、35U.S.C.§119(e)に基づく利益を主張するものであり、その全内容は本明細書に参照として組み込まれる。
(R)-2-アミノ-3-フェニルプロピルカルバメート塩酸塩の溶媒和物フォーム
最小限の2-クロロプロパンを有する(R)-2-アミノ-3-フェニルプロピルカルバメート塩酸塩の合成
Claims (11)
- 7.0、13.6、16.2、17.4、17.8、18.5、21.0、21.7、22.7、23.0、24.0、及び27.3±0.2°2θでピークを有する粉末X線回折パターンを特徴とする、(R)-2-アミノ-3-フェニルプロピルカルバメート塩酸塩((R)-2-amino-3-phenylpropyl carbamate hydrochloride)半水和物の結晶であって、前記結晶は、対象への投与のためのものである、結晶。
- 示差走査熱量測定法(differential scanning calorimetry)により69.1℃の温度で開始し、71.7℃の温度でピークを有する広い吸熱(broad endotherm)、及び182.5℃の温度で開始し、183.6℃の温度でピークを有する急激な吸熱(sharp endotherm)を有することをさらなる特徴とする、請求項1に記載の結晶。
- アセトニトリル/水(95%/5% v/v)中で(R)-2-アミノ-3-フェニルプロピルカルバメート塩酸塩をスラリー化する段階、及び真空ろ過(vacuum filtration)で半水和物の結晶を収集する段階を含む、(R)-2-アミノ-3-フェニルプロピルカルバメート塩酸塩半水和物の結晶を製造する方法であって、前記結晶は、対象への投与のためのものである、方法。
- スラリー化する段階は室温付近で行われる、請求項3に記載の方法。
- スラリー化する段階は、少なくとも約20時間行われる、請求項3または4に記載の方法。
- (R)-2-アミノ-3-フェニルプロピルカルバメート塩酸塩の少なくとも30重量%は、請求項1から2のいずれか一項に記載の結晶である、(R)-2-アミノ-3-フェニルプロピルカルバメート塩酸塩を含む組成物。
- 組成物は、即時放出経口剤形(immediate release oral dosage form)の形態である、請求項6に記載の組成物。
- 組成物は、錠剤(tablet)またはカプセルの形態である、請求項7に記載の組成物。
- 請求項6から8のいずれか一項の記載の組成物であって、それを必要とする対象のナルコレプシー(narcolepsy)、カタプレキシー(cataplexy)、日中の過剰な眠気(excessive daytime sleepiness)、薬物中毒(drug addiction)、性機能障害(sexual dysfunction)、疲労(fatigue)、繊維筋肉痛(fibromyalgia)、注意欠陥/多動性障害(attention deficit/hyperactivity disorder)、下肢静止不能症候群(restless legs syndrome)、うつ病(depression) 、双極性障害(bipolar disorder)または肥満を治療するか、或いはそれを必要とする対象の禁煙を促進するための、
組成物。 - 錠剤は1日1回投与される、請求項9に記載の組成物。
- 錠剤は1日1回以上投与される、請求項9に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021155292A JP2022003062A (ja) | 2016-09-06 | 2021-09-24 | (r)−2−アミノ−3−フェニルプロピルカルバメートの溶媒和物フォーム |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662383822P | 2016-09-06 | 2016-09-06 | |
PCT/US2017/050233 WO2018048871A1 (en) | 2016-09-06 | 2017-09-06 | Solvate form of (r)-2-amino-3-phenylpropyl carbamate |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021155292A Division JP2022003062A (ja) | 2016-09-06 | 2021-09-24 | (r)−2−アミノ−3−フェニルプロピルカルバメートの溶媒和物フォーム |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019535643A JP2019535643A (ja) | 2019-12-12 |
JP2019535643A5 JP2019535643A5 (ja) | 2020-09-24 |
JP7219213B2 true JP7219213B2 (ja) | 2023-02-07 |
Family
ID=61562003
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019512895A Active JP7219213B2 (ja) | 2016-09-06 | 2017-09-06 | (r)-2-アミノ-3-フェニルプロピルカルバメートの溶媒和物フォーム |
JP2021155292A Pending JP2022003062A (ja) | 2016-09-06 | 2021-09-24 | (r)−2−アミノ−3−フェニルプロピルカルバメートの溶媒和物フォーム |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021155292A Pending JP2022003062A (ja) | 2016-09-06 | 2021-09-24 | (r)−2−アミノ−3−フェニルプロピルカルバメートの溶媒和物フォーム |
Country Status (12)
Country | Link |
---|---|
US (3) | US10829443B2 (ja) |
EP (2) | EP3509582B1 (ja) |
JP (2) | JP7219213B2 (ja) |
KR (1) | KR102513800B1 (ja) |
CN (1) | CN109996540A (ja) |
CA (1) | CA3036071A1 (ja) |
DK (1) | DK3509582T3 (ja) |
FI (1) | FI3509582T3 (ja) |
MY (1) | MY197630A (ja) |
PH (1) | PH12019500493A1 (ja) |
SG (1) | SG11201901998WA (ja) |
WO (1) | WO2018048871A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
JP7219213B2 (ja) * | 2016-09-06 | 2023-02-07 | ジャズ ファーマスティカルズ アイルランド リミテッド | (r)-2-アミノ-3-フェニルプロピルカルバメートの溶媒和物フォーム |
US11447448B2 (en) | 2018-08-14 | 2022-09-20 | Glenmark Life Sciences Limited | Process for the preparation of solriamfetol and salt thereof |
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
WO2021001457A1 (en) | 2019-07-04 | 2021-01-07 | Sandoz Ag | Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts |
IT202000013855A1 (it) | 2020-06-10 | 2021-12-10 | Flamma Spa | Un processo per la purificazione del (r)-2-ammino-3-fenilpropil carbammato |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007508293A (ja) | 2003-10-08 | 2007-04-05 | エスケー コーポレイション | 活性アミン基の存在下におけるo−カルバモイル化合物の製造方法 |
JP2008546778A (ja) | 2005-06-22 | 2008-12-25 | エスケー ホルディングス カンパニー リミテッド | 性機能障害を治療する方法 |
JP2016532679A (ja) | 2013-07-18 | 2016-10-20 | ジャズ ファーマスティカルズ インターナショナル スリー リミテッドJazz Pharmaceuticals International Iii Limited | 肥満の治療 |
JP2017512211A (ja) | 2014-02-28 | 2017-05-18 | エスケー バイオファーマスティカルズ カンパニー リミテッド | アミノカルボニルカルバメート化合物 |
JP2019512009A (ja) | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100197892B1 (ko) * | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
ATE238783T1 (de) | 1998-12-23 | 2003-05-15 | Orphan Medical Inc | Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten |
RU2202607C2 (ru) * | 2000-03-03 | 2003-04-20 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" | Штамм бактерий methylophilus methylotrophus - продуцент l-фенилаланина (варианты), способ получения l-фенилаланина |
BRPI0518233A2 (pt) | 2004-10-28 | 2008-11-11 | Sk Corp | terapia adjunta para depressço |
TWI419681B (zh) | 2005-06-08 | 2013-12-21 | Sk Biopharmaceuticals Co Ltd | 胺基甲酸酯用於製造供治療白天過度嗜睡(eds)的藥物之用途 |
JP6095366B2 (ja) | 2009-06-22 | 2017-03-15 | エスケー バイオファーマシューティカルズ カンパニー リミテッド | 疲労を治療又は予防するための方法 |
US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
AU2010316106B2 (en) | 2009-11-06 | 2015-10-22 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
BR112012010648A2 (pt) | 2009-11-06 | 2020-12-01 | Sk Biopharmaceuticals Co., Ltd. | uso de compostos na preparação de composições farmacêuticas para tratar síndrome de fibromialgia e composição farmacêutica |
US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
KR102192554B1 (ko) | 2013-03-13 | 2020-12-18 | 에스케이바이오팜 주식회사 | 탈력발작의 치료 |
KR20210152011A (ko) | 2013-07-12 | 2021-12-14 | 에스케이바이오팜 주식회사 | 금연의 촉진 |
JP7219213B2 (ja) * | 2016-09-06 | 2023-02-07 | ジャズ ファーマスティカルズ アイルランド リミテッド | (r)-2-アミノ-3-フェニルプロピルカルバメートの溶媒和物フォーム |
KR101950254B1 (ko) | 2016-09-21 | 2019-02-20 | 유상신 | 차량탑승자의 부재를 감지하는 지능형 카시트 |
-
2017
- 2017-09-06 JP JP2019512895A patent/JP7219213B2/ja active Active
- 2017-09-06 EP EP17849432.4A patent/EP3509582B1/en active Active
- 2017-09-06 SG SG11201901998WA patent/SG11201901998WA/en unknown
- 2017-09-06 MY MYPI2019001180A patent/MY197630A/en unknown
- 2017-09-06 FI FIEP17849432.4T patent/FI3509582T3/fi active
- 2017-09-06 KR KR1020197011279A patent/KR102513800B1/ko active IP Right Grant
- 2017-09-06 WO PCT/US2017/050233 patent/WO2018048871A1/en unknown
- 2017-09-06 US US16/331,069 patent/US10829443B2/en active Active
- 2017-09-06 CN CN201780065192.6A patent/CN109996540A/zh active Pending
- 2017-09-06 CA CA3036071A patent/CA3036071A1/en not_active Abandoned
- 2017-09-06 EP EP23218015.8A patent/EP4364794A2/en active Pending
- 2017-09-06 DK DK17849432.4T patent/DK3509582T3/da active
-
2019
- 2019-03-06 PH PH12019500493A patent/PH12019500493A1/en unknown
-
2020
- 2020-11-06 US US17/091,222 patent/US11560354B2/en active Active
-
2021
- 2021-09-24 JP JP2021155292A patent/JP2022003062A/ja active Pending
-
2022
- 2022-12-14 US US18/066,000 patent/US20230183172A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007508293A (ja) | 2003-10-08 | 2007-04-05 | エスケー コーポレイション | 活性アミン基の存在下におけるo−カルバモイル化合物の製造方法 |
JP2008546778A (ja) | 2005-06-22 | 2008-12-25 | エスケー ホルディングス カンパニー リミテッド | 性機能障害を治療する方法 |
JP2016532679A (ja) | 2013-07-18 | 2016-10-20 | ジャズ ファーマスティカルズ インターナショナル スリー リミテッドJazz Pharmaceuticals International Iii Limited | 肥満の治療 |
JP2017512211A (ja) | 2014-02-28 | 2017-05-18 | エスケー バイオファーマスティカルズ カンパニー リミテッド | アミノカルボニルカルバメート化合物 |
JP2019512009A (ja) | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
Non-Patent Citations (1)
Title |
---|
芹沢一英,医薬品の多形現象と晶析の化学,2002年09月20日,273-278 |
Also Published As
Publication number | Publication date |
---|---|
PH12019500493A1 (en) | 2019-05-27 |
JP2022003062A (ja) | 2022-01-11 |
EP3509582A4 (en) | 2020-05-13 |
WO2018048871A1 (en) | 2018-03-15 |
KR102513800B1 (ko) | 2023-03-24 |
KR20190065311A (ko) | 2019-06-11 |
MY197630A (en) | 2023-06-29 |
US10829443B2 (en) | 2020-11-10 |
EP3509582A1 (en) | 2019-07-17 |
EP3509582B1 (en) | 2023-12-20 |
DK3509582T3 (en) | 2024-02-12 |
SG11201901998WA (en) | 2019-04-29 |
JP2019535643A (ja) | 2019-12-12 |
US20210053912A1 (en) | 2021-02-25 |
US20230183172A1 (en) | 2023-06-15 |
US20190194126A1 (en) | 2019-06-27 |
FI3509582T3 (fi) | 2024-02-08 |
US11560354B2 (en) | 2023-01-24 |
CA3036071A1 (en) | 2018-03-15 |
EP4364794A2 (en) | 2024-05-08 |
CN109996540A (zh) | 2019-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7219213B2 (ja) | (r)-2-アミノ-3-フェニルプロピルカルバメートの溶媒和物フォーム | |
ES2567077T3 (es) | Cristales novedosos y proceso de 5-({[2-amino-3-(4-carbamoil-2,6-dimetil-fenil)propionil]-[1-(4-fenil-1H-imidazol-2-il)-etil] amino}metil)-2-metoxi-benzoico | |
ES2302011T3 (es) | Sales de meldonio, metodo para su preparacion y composicion farmaceutica basado en las mismas. | |
JP2017206516A (ja) | プリドピジン塩酸塩の新規な多形形態 | |
JP2020530837A (ja) | カルバモイルフェニルアラニノール類縁体およびその使用 | |
RU2650511C2 (ru) | Формы и составы пиримидинилциклопентанового соединения, композиции и способы, относящиеся к ним | |
CA3079196C (en) | Method for preparation of n-acetyl cysteine amide and derivatives thereof | |
CN104470920A (zh) | 固态形式的维罗菲尼胆碱盐 | |
WO2011047767A1 (en) | Novel polymorphic forms of (s)-2-[-4-(3-fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof | |
ES2658862T3 (es) | Forma sólida aislada de monoclorhidrato de anamorelina con una relación molar de cloruro:anamorelina baja y un contenido de disolventes orgánicos residuales bajo | |
JP2014516341A (ja) | アゴメラチンの新しい結晶形vii、その調製方法及び使用並びにこれを含有する医薬組成物 | |
KR20140111044A (ko) | 구연산아일데나필 결정 형태 o 및 그의 제조방법과 용도 | |
JP6610793B2 (ja) | 環状アミン誘導体の結晶及びその医薬用途 | |
ES2587064T3 (es) | Sales fumarato novedosas de un antagonista del receptor de histamina H3 | |
AU2001272872A1 (en) | Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro -2-naphthyl)-4-morpholinobenzamide | |
WO2002008212A1 (en) | Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide | |
CN104744464B (zh) | 伊曲茶碱晶型 | |
JP4015954B2 (ja) | トシル酸スプラタスト結晶 | |
WO2004067496A9 (en) | Crystalline form of nateglinide | |
US20080234286A1 (en) | Stable amorphous imatinib mesylate and production process therefor | |
CN104447542A (zh) | 博舒替尼一水合物及其制备方法 | |
US8754129B2 (en) | Crystalline vorinostat form VI | |
CN104530051B (zh) | 稳定的(6r,s)-5-甲基四氢叶酸晶型及其制备方法 | |
TW200914024A (en) | Mono-hydrochloric salts of an inhibitor of histone deacetylase | |
JPS5916873A (ja) | 5−オキソ−2−ピロリジンプロパン酸および誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20191211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200811 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200811 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210603 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210924 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211223 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220913 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230126 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7219213 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |